Hepatology

These disruptions may play a pathophysiological role in metabolic dysfunction-associated steatotic liver disease development.

Recent research highlights the discovery of 17 novel loci associated with liver triglycerides and 9 linked to liver inflammation.

Recent studies have highlighted the potential of sodium-glucose cotransporter 2 inhibitors, especially ertugliflozin, in improving outcomes for patients with NAFLD and T2DM.

Frailty has emerged as a therapeutic target in advanced chronic liver disease management, with non-pharmacological interventions showing promise.

Lifestyle modifications, particularly dietary changes, have shown potential in reversing MASLD and steatohepatitis.

A recent clinical trial investigated combining time-restricted feeding and flaxseed for MASLD treatment.

Among serum biomarkers, the FIB-4 and APRI scores are widely recognised for assessing advanced fibrosis and cirrhosis.

This study examined the efficacy and safety of pemafibrate in 360 patients with MASLD and hypertriglyceridaemia.